IL-1RA Porcine binds non-productively to the IL-1 receptor (IL-1R), blocking IL-1α and IL-1β from initiating pro-inflammatory signaling . This inhibition modulates immune responses by:
Suppressing innate immunity: Reduces phagocytosis, MHC II (SLA-DR), and CD86 expression in porcine monocyte-derived dendritic cells (MoDCs) .
Regulating adaptive immunity: Inhibits T lymphocyte differentiation and proliferation while promoting regulatory T cell (Treg) induction .
Synergizing with IL-10: Amplifies anti-inflammatory effects, particularly in PRRSV-infected pigs .
Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) exploits IL-1RA to evade host immunity:
In vitro studies: PRRSV-infected MoDCs show reduced IFNA and IL1 gene expression, impaired antigen presentation, and suppressed T cell activation .
Treg induction: IL-1RA collaborates with IL-10 to drive Treg differentiation, dampening inflammatory responses .
IL-1RA Porcine mitigates IL-1α-mediated cartilage degradation:
Explant model: Co-treatment with IL-1RA and 1% lidocaine reduced sulfated glycosaminoglycan (sGAG) release by 60–70%, comparable to IL-1RA alone .
Histopathology: Modified Mankin scores confirmed reduced cartilage degradation in treated explants .
Treatment | sGAG Release Inhibition | Key Outcome |
---|---|---|
IL-1RA alone | 70% | Effective cartilage protection |
IL-1RA + 1% lidocaine | 65% | Synergy without efficacy loss |
Storage: Lyophilized IL-1RA Porcine remains stable for 3 weeks at room temperature and longer at -18°C with carrier proteins (e.g., 0.1% HSA) .
Reconstitution: Optimal solubility (>100 µg/mL) in sterile water, compatible with physiological buffers .
Anti-inflammatory interventions: IL-1RA Porcine is explored for joint injury management, combining pain relief (via lidocaine) and inflammation suppression .
Veterinary use: Potential applications in treating lameness and inflammatory conditions in livestock .
The ED50, determined by the inhibition of IL-1α-dependent proliferation in murine D10S cells, is less than 50 ng/ml. This corresponds to a specific activity exceeding 2.0 × 104 IU/mg in the presence of 75 pg/ml of recombinant Porcine IL-1α.
IL-1RA competitively binds to IL-1 receptor (IL-1R) and subsequently inhibits IL-1-induced signaling cascades . In porcine models, IL-1RA has been extensively studied in the context of PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) infection, where it demonstrates significant immunomodulatory effects. This protein represents a key regulator during the early phase of immune responses, similar to its role in other species .
The mechanism involves direct competition with IL-1 for receptor binding sites without triggering signal transduction, effectively blocking the pro-inflammatory actions of IL-1. This competitive inhibition affects multiple downstream pathways involved in inflammation and immune cell activation.
During PRRSV infection, increased levels of IL-1RA are observed both in vitro and in infected pigs . This upregulation appears to be part of the virus-induced immunosuppression strategy. The virus exploits this host mechanism to dampen immune responses, similar to strategies employed by other pathogens such as Yersinia pestis and HIV in their respective hosts .
The temporal dynamics of IL-1RA production during infection are particularly important, as this protein appears to have its most significant immunomodulatory effects during the early phase of the immune response.
While the search results don't exhaustively list all cellular sources, they indicate that monocyte-derived dendritic cells (MoDC) and peripheral blood mononuclear cells (PBMC) produce measurable amounts of IL-1RA, particularly when infected with PRRSV . These cell populations can be cultured in vitro to study IL-1RA production under various experimental conditions.
Enzyme-linked immunosorbent assay (ELISA) is the primary method for measuring IL-1RA protein levels in porcine samples. Specifically, the search results mention using porcine IL-1Ra ELISA (CUSABIO, Wuhan, China) to measure levels in culture supernatants . The protocol involves:
Culturing PBMC (2 × 10^6 cells/well) or MoDC (1 × 10^6 cells/well) with viral or mock stimulation
Incubating cells at 37°C and 5% CO2 for 48 hours
Collecting culture supernatants
Performing the ELISA according to manufacturer's instructions
The sensitivity and specificity of these assays are crucial considerations, as cross-reactivity with other cytokines or species variants could affect measurement accuracy.
To study the functional importance of IL-1RA in porcine systems, researchers have used neutralizing antibodies. The methodology involves:
Pre-treating cells with 10 ng/mL polyclonal goat anti-porcine IL-1Ra antibody (R&D system, clone AF780)
Using polyclonal goat IgG isotype control antibody as an appropriate experimental control
Applying the neutralizing antibody at 2 hours post-inoculation (e.g., with PRRSV)
Continuing the culture for an additional 22 hours before assessing immune parameters
This approach allows researchers to assess the specific contribution of IL-1RA to observed immunological phenomena by selectively blocking its activity.
Based on the search results, the following conditions have been successfully employed:
Cell types: Monocyte-derived dendritic cells (MoDC), peripheral blood mononuclear cells (PBMC), or peripheral blood lymphocytes (PBL)
Culture medium: Complete RPMI containing advanced RPMI, 10% FBS, 2 mM L-glutamine, antibiotic/antimycotic solution, 25 mM HEPES, and 50 μM β-mercaptoethanol
Growth factors for MoDC differentiation: 10 ng/mL porcine recombinant IL-4 and 25 ng/mL porcine recombinant GM-CSF for 7 days
Culture conditions: 37°C and 5% CO2
Cell density: Typically 1-2 × 10^6 cells/well in 24-well plates
These standardized conditions allow for reproducible experiments when studying IL-1RA production and its effects on various immune parameters.
IL-1RA has significant effects on innate immune functions in porcine cells, particularly:
Reduced phagocytosis: PRRSV-induced IL-1RA reduces the phagocytic activity of monocyte-derived dendritic cells (MoDC), which was demonstrated using inactivated E. coli-FITC assays
Decreased expression of key surface molecules: IL-1RA reduces surface expression of MHC II (SLA-DR) and CD86 on MoDC, potentially impairing antigen presentation and co-stimulation
Downregulation of important cytokine genes: IL-1RA leads to downregulation of IFNA and IL1 gene expression in MoDC, potentially compromising antiviral and inflammatory responses
These effects collectively contribute to impaired innate immune function, which may benefit pathogen survival during infection.
IL-1RA significantly modulates adaptive immune responses in porcine systems:
T lymphocyte differentiation: PRRSV-induced IL-1RA inhibits T lymphocyte differentiation, potentially affecting the development of effective adaptive immunity
T cell proliferation: IL-1RA secreted by PRRSV-infected MoDC inhibits T lymphocyte proliferation, limiting clonal expansion during immune responses
Regulatory T cell induction: IL-1RA contributes to the differentiation of regulatory T lymphocytes (Treg), which can further suppress immune responses
Selective effects on cytokine production: Interestingly, IL-1RA does not affect IFN-γ production by T cells, suggesting selective rather than global immunosuppression
These effects on adaptive immunity may explain how pathogens that induce IL-1RA can establish persistent infections by compromising host defense mechanisms.
While IL-1RA primarily functions by blocking IL-1 signaling, its interactions with other cytokines create a complex regulatory network:
Relationship with IL-10: Although PRRSV-induced IL-1RA was not directly linked to IL-10 production, it contributed collaboratively with IL-10 to regulatory T cell induction
Impact on inflammatory cytokine expression: IL-1RA downregulates IL1 gene expression, creating a negative feedback loop that may further dampen inflammatory responses
This suggests that IL-1RA functions within a broader cytokine network to coordinate appropriate immune responses or, in the case of pathogen exploitation, to promote immunosuppression.
Recent research has explored the combination of IL-1RA with local anesthetics for joint injury treatment:
Efficacy of combination therapy: The combination of IL-1Ra and lidocaine (1%) was found to be as efficacious as IL-1Ra treatment alone in mitigating biological cartilage injury due to IL-1α in an explant model
Storage stability: This combination remains stable when reagents are stored in advance at varying temperatures (room temperature or 4°C), providing clinically relevant information for potential therapeutic applications
Dual-action benefits: This combination could simultaneously provide pain relief (lidocaine) and block inflammation-induced catabolism of joint tissues (IL-1RA)
This research suggests potential translational applications for IL-1RA in veterinary medicine for treating joint injuries in pigs, with possible relevance to human medicine as well.
Porcine models have provided valuable insights into IL-1RA's role in cardiovascular diseases:
Neointima formation: In porcine coronary arteries, the neointima response to balloon angioplasty (modeling arterial wall rupture) is reduced by a 14-day subcutaneous infusion of IL-1RA
Translational relevance: These findings in porcine models complement studies in mouse models showing that IL-1RA inhibits intimal fatty streak formation and that IL-1 signaling deficiency reduces atherosclerosis
Blood pressure regulation: While not directly studied in porcine models, related mouse studies suggest IL-1RA may have beneficial effects on blood pressure during atherogenic conditions
These findings highlight the potential value of porcine models for studying IL-1RA's cardiovascular effects, with implications for both veterinary and human medicine.
The search results outline a specific methodology for quantifying gene expression in porcine samples:
RNA extraction: Total mRNAs are isolated from cells (2 × 10^6 cells/reaction) using a total mRNA extraction kit
Quality assessment: Extracted mRNAs should be assessed by NanoDrop
cDNA synthesis: mRNA is converted to cDNA using a cDNA synthesis kit
qPCR approach: SYBR green-based qPCR using specific primer sets for the genes of interest
Normalization: Ct values of each gene should be normalized against a housekeeping gene, commonly GAPDH
Analysis method: Differences in Ct values between treatment groups should be analyzed using the 2^-ΔΔCt formula
This methodology allows for reliable quantification of gene expression changes in response to experimental manipulations.
Designing experiments to delineate direct versus indirect effects of IL-1RA requires careful consideration:
Neutralizing antibody approaches: Using anti-IL-1RA antibodies at different time points can help establish when IL-1RA's effects are most critical
Recombinant protein studies: Comparing effects of recombinant IL-1RA alone versus in combination with other cytokines can help identify synergistic or antagonistic relationships
Gene expression timing: Analyzing the temporal sequence of gene expression changes can help establish cause-and-effect relationships
Cell isolation techniques: Using purified cell populations versus mixed cultures can help determine which effects are direct cellular responses versus those mediated by intercellular communication
For example, the research showing that PRRSV-induced IL-1RA inhibits T lymphocyte differentiation used supernatants from infected cells treated with anti-IL-1RA antibodies to determine that this effect was directly attributable to IL-1RA .
When working with porcine IL-1 family proteins, researchers should consider:
ELISA sensitivity: For related assays like the Porcine IL-1β ELISA, the minimum detectable dose ranges from 2.7-13.6 pg/mL with a mean of 6.7 pg/mL
Calibration standards: Assays are typically calibrated against highly purified E. coli-expressed recombinant porcine proteins
Cross-reactivity: Specificity testing is essential to ensure assays recognize only the intended target and not related family members
Sample type considerations: Detection rates vary by sample type - for example, IL-1β is detectable in 21% of serum samples versus 80% of heparin plasma samples
These considerations are crucial for generating reliable and reproducible data when studying IL-1RA and related cytokines in porcine systems.
Immune Parameter | Effect of IL-1RA | Experimental Approach Used |
---|---|---|
Phagocytosis | Reduction | E. coli-FITC uptake assay with anti-IL-1RA neutralization |
MHC II (SLA-DR) expression | Downregulation | Flow cytometry after IL-1RA neutralization |
CD86 expression | Downregulation | Flow cytometry after IL-1RA neutralization |
IFNA gene expression | Suppression | qPCR with GAPDH normalization |
IL1 gene expression | Suppression | qPCR with GAPDH normalization |
T lymphocyte differentiation | Inhibition | Culture with PRRSV-infected MoDC supernatants ± anti-IL-1RA |
T lymphocyte proliferation | Inhibition | BrdU incorporation assay |
IFN-γ production | No significant effect | Culture with supernatants from infected cells |
Regulatory T cell induction | Enhancement | Co-cultural functional assay (with IL-10) |
Parameter | Recommended Condition | Notes |
---|---|---|
Cell density | 1-2 × 10^6 cells/well | In 24-well plates for most assays |
Culture medium | Complete RPMI | Advanced RPMI with 10% FBS, 2 mM L-glutamine, antibiotics, 25 mM HEPES, 50 μM β-mercaptoethanol |
MoDC differentiation | 7 days | With 10 ng/mL porcine IL-4 and 25 ng/mL GM-CSF |
IL-1RA neutralization | 10 ng/mL anti-IL-1RA antibody | Applied 2 hours post-stimulation |
Incubation conditions | 37°C, 5% CO2 | Standard for mammalian cell culture |
Optimal time for measuring IL-1RA | 48 hours post-stimulation | For culture supernatants by ELISA |
Interleukin-1 Receptor Antagonist (IL-1Ra) is a naturally occurring anti-inflammatory protein that plays a crucial role in regulating the immune response. It is part of the interleukin-1 family of cytokines, which are involved in various inflammatory processes. The recombinant form of IL-1Ra, derived from porcine sources, has been developed to study its effects and potential therapeutic applications.
IL-1Ra was first discovered in 1984 in the urine and serum of patients with leukemia and in the supernatant of cultured monocytes . It was named for its ability to competitively bind to the interleukin-1 receptor, thereby antagonizing the function of interleukin-1 (IL-1). This discovery opened up new avenues for research into the regulation of inflammatory responses and the development of anti-inflammatory therapies.
IL-1Ra works by binding to the interleukin-1 receptor without activating it, effectively blocking the binding of pro-inflammatory cytokines such as IL-1α and IL-1β . This inhibition helps to reduce inflammation and protect against immune dysregulation and uncontrolled systemic inflammation triggered by various stimulatory agents, including pathogens .
The recombinant form of IL-1Ra derived from porcine sources has been developed to explore its potential in veterinary medicine and research. Porcine IL-1Ra has been studied for its immunomodulatory effects, particularly in the context of porcine reproductive and respiratory syndrome virus (PRRSV) infection . Research has shown that PRRSV-induced IL-1Ra can impair innate and adaptive immune responses, highlighting its role in viral immunosuppression .
Recombinant IL-1Ra, such as anakinra, has been used in the treatment of autoimmune diseases like rheumatoid arthritis . Anakinra is a slightly modified version of IL-1Ra that has shown efficacy in reducing the signs and symptoms of rheumatoid arthritis when used in combination with methotrexate . The success of anakinra in human medicine has spurred interest in exploring the therapeutic potential of recombinant IL-1Ra in veterinary applications.